Opendata, web and dolomites

Trep-AB SIGNED

Repurposing clinically approved antibacterial drugs for treponematoses therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Trep-AB project word cloud

Explore the words cloud of the Trep-AB project. It provides you a very rough idea of what is the project "Trep-AB" about.

global    options    penetration    experimentally    microorganism    speaking    biological    advantage    susceptibility    tremendous    conducting    macrolide    standard    good    candidate    clarify    disseminate    resource    treponematoses    human    rabbits    cns    broadly    randomized    strains    expertise    stages    nervous    reduce    preliminary    syphilis    prediction    events    drug    antibacterial    central    allergy    acquire    current    mutations    infection    team    incorporate    recurrent    lesion    campaign    prioritized    eradication    computational    yaws    regimens    shortage    culture    cure    candidates    infected    profile    spirochetes    validated    survive    treponema    confer    risk    shows    jeopardize    burden    trials    combination    basis    patients    unknown    lactams    grown    penicillin    antibiotics    treatment    drugs    resistance    therapeutic    antibiotic    azithromycin    treponemal    oral    resistant    efficacious    clinical    restricted    investigational    similarity    injectable    confirmed    bacteria    pallidum    efficacy   

Project "Trep-AB" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA 

Organization address
address: CARRETERA DE CANYET HOSPITAL GERMANS TRIAS I PUJOL PLANTA 2
city: BADALONA
postcode: 8916
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙498˙790 €
 EC max contribution 1˙498˙790 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2025-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA ES (BADALONA) coordinator 1˙150˙678.00
2    UNIVERSITY OF WASHINGTON US (SEATTLE WA) participant 348˙111.00

Map

 Project objective

Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a research program to have other validated treatment options with good CNS penetration that are efficacious for all the stages of treponemal infection. Our preliminary results using computational prediction of drug activity based on similarity to drugs with known activity against T.p. and other spirochetes shows several candidate antibiotics. I will take advantage of recent developments in culture methods for determination of drug susceptibility to test 20 prioritized drugs. These results will be confirmed in experimentally infected rabbits treated with the investigational drugs and assessed for lesion development and T.p. burden. My second approach will exploit the established expertise of my team conducting randomized clinical trials to evaluate the efficacy of the 2 most promising candidates compared to standard treatment to cure patients with syphilis/yaws. Such studies will incorporate in-depth studies of recurrent events among study participants, to further clarify the biological basis and identify mutations that confer resistance to B-lactams. New antibacterial oral drugs for the treatment of treponematoses will be a tremendous resource in case of penicillin treatment-failure, resistance, shortage, allergy, or for use in yaws combination regimens to reduce the likelihood of resistance selection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREP-AB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREP-AB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Cu4Peroxide (2020)

The electrochemical synthesis of hydrogen peroxide

Read More  

CoolNanoDrop (2019)

Self-Emulsification Route to NanoEmulsions by Cooling of Industrially Relevant Compounds

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More